Insider · CIK 0001390798
Mark Anthony McCamish
Files at AVDL (AVADEL PHARMACEUTICALS PLC). First filing -, latest -.
In brief
Mark Anthony McCamish files SEC Form 4 as director at AVDL (AVADEL PHARMACEUTICALS PLC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark Anthony McCamish has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Ordinary Shares | -22,000 | $21.00 | $462k | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Ordinary Sharesindirect: By McCamish Charitable Remainder Trust | -67,025 | $21.00 | $1.4M | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -60,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -50,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -33,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,000 | - | - | 0 | Feb 12, 2026 |
| Feb 12, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,000 | - | - | 0 | Feb 12, 2026 |
| Feb 4, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | GGift Ordinary Sharesindirect: By Matthew 5 LLC | -67,025 | $0.00 | $0 | 0 | Feb 6, 2026 |
| Feb 4, 2026 | AVDL AVADEL PHARMACEUTICALS PLC | GGift Ordinary Sharesindirect: By McCamish Charitable Remainder Trust | +67,025 | $0.00 | $0 | 67,025 | Feb 6, 2026 |
| Jul 29, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Ordinary Shares | +11,000 | $0.00 | $0 | 22,000 | Jul 31, 2025 |
| Jul 29, 2025 | AVDL AVADEL PHARMACEUTICALS PLC | AGrant or award Stock Option (Right to Buy)derivative | +11,000 | $0.00 | $0 | 11,000 | Jul 31, 2025 |
Questions about Mark Anthony McCamish
Answered from the filings on this page, as of the latest one.
Is Mark Anthony McCamish buying or selling?
Mark Anthony McCamish has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark Anthony McCamish's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Anthony McCamish has 0.
Where does Mark Anthony McCamish file Form 4?
Mark Anthony McCamish has filed Form 4 at AVDL (AVADEL PHARMACEUTICALS PLC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.